Israel’s RedHill Biopharma announced success last week in a major clinical trial of a new drug to prevent nausea in cancer patients.
The once-a-day pill RHB-102, which has now passed a trial corresponding to a Phase III clinical trial, will compete with leading anti-nausea drug Zofran, made by GlaxoSmithKline, which is taken several times a day.
Advertisement
Redhill will apply to the FDA for a pre-New Drug Application hearing for market approval in a few weeks.
Anti-nausea medications are estimated to be worth $2 billion around the world, according to a report in Globes online business news.
Advertisement